Category: Replacement Heart Valves
A federal appeals court stays a ban on U.S. sales of Medtronic's CoreValve replacement heart valve "pending further notice" in a patent infringement battle with Edwards Lifesciences and its Sapien transcatheter aortic valve implant.
Edwards Lifesciences urges a federal appeals court to ignore Medtronic's alleged 'scare tactics' over a pending ban on its CoreValve replacement heart valve.
UPDATED April 21, 2014, at 12:30 p.m. with comment from Medtronic.
UPDATED April 21, 2014, at 3:45 p.m. with comment from Edwards Lifesciences.
Cardiac Dimensions raises $20 million from a syndicate of international investors for its Carillon mitral valve implant.
Cardiac Dimensions said it raised $20 million from a syndicate of international investors for its Carillon mitral valve implant.
M.H. Carnegie & Co. and Lumira Capital led the round for Kirkland, Wash.-based Cardiac Dimensions, according to a press release. Investors in Australia, the U.S. and Canada also participated, the company said.
A U.S. District Judge defends a ban on Medtronic's newly approved CoreValve transcatheter aortic valve implantation system, saying the company willfully ignored the law in bringing the device to the U.S. after it was found to infringe on a patent held by Edwards Lifesciences.
U.S. District Judge Gregory Sleet chided Medtronic (NYSE:MDT) this week after issuing a preliminary ban on the medtech titan's CoreValve transcatheter aortic valve implantation system.
Medtech titan Medtronic plans to seek immediate appeal of a preliminary court injunction banning sales of its CoreValve transcatheter aortic valve implantation system.
Edwards Lifesciences lands a preliminary injunction limiting Medtronic from selling its CoreValve transcatheter aortic valve implantation system in the U.S.
Minnesota-based Tendyne Holdings raises $25 million in a Series C funding round supporting its transcatheter mitral valve implantation systems for treating mitral regurgitation.
Medtech startup Tendyne Holdings landed $25 million in Series C funding, planning on using the new cash for further research & development of its transcatheter mitral valve technology.
The 4-year-old company's device provides minimally invasive treatment of mitral regurgitation. Tendyne is working on engineering an implantation system that would allow physicians to re-position or retrieve the valve even after full deployment.